array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(28) "Bristol-Myers Squibb Company"
["slug"]=>
string(37) "81631-us-bristol-myers-squibb-company"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/7b41874f-2658-484b-890c-9b9bd5a41f13"
["description"]=>
string(1400) "At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome.
Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients.
Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do.
Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html"
["address_street"]=>
string(19) "430 E 29TH St FL 14"
["address_place"]=>
string(8) "New York"
["address_region"]=>
string(8) "New York"
["founding_date"]=>
string(10) "1887-02-28"
["website_domain"]=>
string(7) "bms.com"
["website_url"]=>
string(19) "https://www.bms.com"
["industry_codes"]=>
array(1) {
[0]=>
string(27) "Pharmaceutical Preparations"
}
["employee_count"]=>
int(1200)
["article_count"]=>
int(2495)
}
["articles"]=>
array(9) {
[0]=>
array(7) {
["title_en"]=>
string(98) "Risk Adjusted Net Present Value: What is the current valuation of Bristol-Myers Squibb's Ezobresib"
["snippet_en"]=>
string(163) "Ezobresib is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase II program in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)."
["url"]=>
string(105) "https://www.pharmaceutical-technology.com/data-insights/ezobresib-bristol-myers-squibb-net-present-value/"
["image_url"]=>
NULL
["source"]=>
string(29) "pharmaceutical-technology.com"
["publication_date"]=>
string(10) "2023-09-19"
["categories"]=>
array(1) {
[0]=>
string(9) "Valuation"
}
}
[1]=>
array(7) {
["title_en"]=>
string(100) "Risk Adjusted Net Present Value: What is the current valuation of Bristol-Myers Squibb's Admilparant"
["snippet_en"]=>
string(169) "Admilparant is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase II program in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease)."
["url"]=>
string(107) "https://www.pharmaceutical-technology.com/data-insights/admilparant-bristol-myers-squibb-net-present-value/"
["image_url"]=>
NULL
["source"]=>
string(29) "pharmaceutical-technology.com"
["publication_date"]=>
string(10) "2023-09-19"
["categories"]=>
array(1) {
[0]=>
string(9) "Valuation"
}
}
[2]=>
array(7) {
["title_en"]=>
string(99) "Risk Adjusted Net Present Value: What is the current valuation of Bristol-Myers Squibb's BMS-986263"
["snippet_en"]=>
string(153) "BMS-986263 is an antisense rnai oligonucleotide commercialized by Bristol-Myers Squibb, with a leading Phase II program in Idiopathic Pulmonary Fibrosis."
["url"]=>
string(106) "https://www.pharmaceutical-technology.com/data-insights/bms-986263-bristol-myers-squibb-net-present-value/"
["image_url"]=>
NULL
["source"]=>
string(29) "pharmaceutical-technology.com"
["publication_date"]=>
string(10) "2023-06-06"
["categories"]=>
array(2) {
[0]=>
string(9) "Valuation"
[1]=>
string(17) "Academic Research"
}
}
[3]=>
array(7) {
["title_en"]=>
string(99) "Risk Adjusted Net Present Value: What is the current valuation of Bristol-Myers Squibb's BMS-986278"
["snippet_en"]=>
string(168) "BMS-986278 is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase II program in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease)."
["url"]=>
string(106) "https://www.pharmaceutical-technology.com/data-insights/bms-986278-bristol-myers-squibb-net-present-value/"
["image_url"]=>
NULL
["source"]=>
string(29) "pharmaceutical-technology.com"
["publication_date"]=>
string(10) "2023-06-06"
["categories"]=>
array(2) {
[0]=>
string(9) "Valuation"
[1]=>
string(17) "Academic Research"
}
}
[4]=>
array(7) {
["title_en"]=>
string(40) "Is Bristol-Myers Squibb Stock a Buy Now?"
["snippet_en"]=>
string(68) "The stock faces risks, but are they outweighed by its low valuation?"
["url"]=>
string(82) "https://www.fool.com/investing/2023/05/11/is-bristol-myers-squibb-stock-a-buy-now/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/26e59598-ac7d-40f5-935e-9050dc450df6"
["source"]=>
string(8) "fool.com"
["publication_date"]=>
string(10) "2023-05-11"
["categories"]=>
array(4) {
[0]=>
string(9) "Valuation"
[1]=>
string(24) "Systemic Risk Management"
[2]=>
string(12) "Stock Market"
[3]=>
string(24) "Stock Research & Ratings"
}
}
[5]=>
array(7) {
["title_en"]=>
string(100) "Risk Adjusted Net Present Value: What is the current valuation of Bristol-Myers Squibb's Mezigdomide"
["snippet_en"]=>
string(136) "Mezigdomide is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase III program in Refractory Multiple Myeloma."
["url"]=>
string(107) "https://www.pharmaceutical-technology.com/data-insights/mezigdomide-bristol-myers-squibb-net-present-value/"
["image_url"]=>
NULL
["source"]=>
string(29) "pharmaceutical-technology.com"
["publication_date"]=>
string(10) "2023-02-23"
["categories"]=>
array(1) {
[0]=>
string(9) "Valuation"
}
}
[6]=>
array(7) {
["title_en"]=>
string(103) "Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's Branebrutinib?"
["snippet_en"]=>
string(130) "Branebrutinib is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase II program in Rheumatoid Arthritis."
["url"]=>
string(109) "https://www.pharmaceutical-technology.com/data-insights/branebrutinib-bristol-myers-squibb-net-present-value/"
["image_url"]=>
NULL
["source"]=>
string(29) "pharmaceutical-technology.com"
["publication_date"]=>
string(10) "2023-02-23"
["categories"]=>
array(1) {
[0]=>
string(9) "Valuation"
}
}
[7]=>
array(7) {
["title_en"]=>
string(99) "Risk Adjusted Net Present Value: What is the current valuation of Bristol-Myers Squibb's Danicamtiv"
["snippet_en"]=>
string(129) "Danicamtiv is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase II program in Dilated Cardiomyopathy."
["url"]=>
string(106) "https://www.pharmaceutical-technology.com/data-insights/danicamtiv-bristol-myers-squibb-net-present-value/"
["image_url"]=>
NULL
["source"]=>
string(29) "pharmaceutical-technology.com"
["publication_date"]=>
string(10) "2023-02-22"
["categories"]=>
array(1) {
[0]=>
string(9) "Valuation"
}
}
[8]=>
array(7) {
["title_en"]=>
string(97) "Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's ARX-720?"
["snippet_en"]=>
string(149) "ARX-720 is a recombinant protein commercialized by Bristol-Myers Squibb, with a leading Phase II program in Congestive Heart Failure (Heart Failure)."
["url"]=>
string(103) "https://www.pharmaceutical-technology.com/data-insights/arx-720-bristol-myers-squibb-net-present-value/"
["image_url"]=>
NULL
["source"]=>
string(29) "pharmaceutical-technology.com"
["publication_date"]=>
string(10) "2023-02-22"
["categories"]=>
array(2) {
[0]=>
string(9) "Valuation"
[1]=>
string(6) "Outage"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(254)
}
[1]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(163)
}
[2]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(151)
}
[3]=>
array(2) {
["name"]=>
string(17) "Academic Research"
["count"]=>
int(94)
}
[4]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(89)
}
[5]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(76)
}
[6]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(74)
}
[7]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(64)
}
[8]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(63)
}
[9]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(60)
}
[10]=>
array(2) {
["name"]=>
string(6) "Merger"
["count"]=>
int(60)
}
[11]=>
array(2) {
["name"]=>
string(17) "Energy Management"
["count"]=>
int(56)
}
[12]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(54)
}
[13]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(47)
}
[14]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(47)
}
[15]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(45)
}
[16]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(45)
}
[17]=>
array(2) {
["name"]=>
string(46) "Management of Legal and Regulatory Environment"
["count"]=>
int(42)
}
[18]=>
array(2) {
["name"]=>
string(8) "Verdicts"
["count"]=>
int(39)
}
[19]=>
array(2) {
["name"]=>
string(25) "Business Model Resilience"
["count"]=>
int(35)
}
[20]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(35)
}
[21]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(33)
}
[22]=>
array(2) {
["name"]=>
string(5) "Award"
["count"]=>
int(32)
}
[23]=>
array(2) {
["name"]=>
string(14) "Issuing Shares"
["count"]=>
int(28)
}
[24]=>
array(2) {
["name"]=>
string(11) "Competition"
["count"]=>
int(27)
}
[25]=>
array(2) {
["name"]=>
string(8) "Epidemic"
["count"]=>
int(26)
}
[26]=>
array(2) {
["name"]=>
string(12) "Going Public"
["count"]=>
int(24)
}
[27]=>
array(2) {
["name"]=>
string(10) "Divestment"
["count"]=>
int(22)
}
[28]=>
array(2) {
["name"]=>
string(9) "Valuation"
["count"]=>
int(21)
}
[29]=>
array(2) {
["name"]=>
string(15) "Blogs & Columns"
["count"]=>
int(21)
}
}
}
81631-us-bristol-myers-squibb-company
Bristol-Myers Squibb Company
Location
New York
Founded
1887-02-28
Website
https://www.bms.com
Articles
2495 Articles
Category
Pharmaceutical Preparations
Description
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome.
Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients.
Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do.
Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html
Ezobresib is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase II program in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF).
Admilparant is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase II program in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease).
BMS-986263 is an antisense rnai oligonucleotide commercialized by Bristol-Myers Squibb, with a leading Phase II program in Idiopathic Pulmonary Fibrosis.
BMS-986278 is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase II program in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease).
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
